BR112013012040A2 - tratamento de câncer com dosagens elevadas de proteínas de fusão fdfr1 solúveis - Google Patents

tratamento de câncer com dosagens elevadas de proteínas de fusão fdfr1 solúveis

Info

Publication number: BR112013012040A2
Authority: BR; Brazil
Prior art keywords: fdfr1; soluble; fusion proteins; cancer treatment; dose cancer
Prior art date: 2010-11-15

Application number

BR112013012040A

Other languages

English (en)

Inventor

Harold Keer

Original Assignee

Five Prime Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-15

Filing date

2011-11-14

Publication date

2016-08-16

2011-11-14 Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc

2016-08-16 Publication of BR112013012040A2 publication Critical patent/BR112013012040A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

BR112013012040A 2010-11-15 2011-11-14 tratamento de câncer com dosagens elevadas de proteínas de fusão fdfr1 solúveis BR112013012040A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41394010P	2010-11-15	2010-11-15
US42146210P	2010-12-09	2010-12-09
PCT/US2011/060661 WO2012068030A1 (en)	2010-11-15	2011-11-14	Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins

Publications (1)

Publication Number	Publication Date
BR112013012040A2 true BR112013012040A2 (pt)	2016-08-16

Family

ID=44993965

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BR112013012041A BR112013012041A2 (pt)	2010-11-15	2011-11-14	''terapias de combinações de domínio extracelular fgfr1"
BR112013012040A BR112013012040A2 (pt)	2010-11-15	2011-11-14	tratamento de câncer com dosagens elevadas de proteínas de fusão fdfr1 solúveis

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BR112013012041A BR112013012041A2 (pt)	2010-11-15	2011-11-14	''terapias de combinações de domínio extracelular fgfr1"

Country Status (14)

Country	Link
EP (2)	EP2640377B1 (pt)
JP (4)	JP5945277B2 (pt)
KR (3)	KR101910779B1 (pt)
CN (2)	CN107050426A (pt)
AU (2)	AU2011329127B2 (pt)
BR (2)	BR112013012041A2 (pt)
CA (2)	CA2817583A1 (pt)
EA (2)	EA025828B1 (pt)
IL (2)	IL226252B (pt)
MX (2)	MX2013005388A (pt)
NZ (4)	NZ610487A (pt)
SG (2)	SG190248A1 (pt)
WO (2)	WO2012068032A1 (pt)
ZA (2)	ZA201303501B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8481038B2 (en)	2010-11-15	2013-07-09	Five Prime Therapeutics, Inc.	Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2012318247B2 (en)	2011-11-14	2015-12-17	Five Prime Therapeutics, Inc.	Methods of treating cancer
JP2016526016A (ja) *	2013-05-01	2016-09-01	ファイヴプライムセラピューティクスインク	がんを治療する方法
CA2909689A1 (en) *	2013-05-23	2014-11-27	Five Prime Therapeutics, Inc.	Methods of treating cancer
JP6908998B2 (ja) *	2013-07-05	2021-07-28	ステラー・バイオウム・インコーポレーテッド	口腔組成物
WO2015066452A2 (en) *	2013-11-01	2015-05-07	Foundation Medicine, Inc.	Methods of treating pediatric cancers
EP3411399A4 (en) *	2016-02-04	2019-10-16	Jinsong Ni	SYNERGISTIC DRUG-MEDICINAL SYNERGY TECHNOLOGY FOR THE TREATMENT OF DISEASES

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
DE68925966T2 (de)	1988-12-22	1996-08-29	Kirin Amgen Inc	Chemisch modifizierte granulocytenkolonie erregender faktor
US5288855A (en)	1989-01-23	1994-02-22	Farmitalia Carlo Erba	Extracellular form of the human fibroblast growth factor receptor
CA2063431C (en)	1989-07-06	2002-10-29	Lewis T. Williams	Receptors for fibroblast growth factors
US6552170B1 (en)	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
ATE243253T1 (de)	1990-07-06	2003-07-15	Rhone Poulenc Rorer Internat H	Rezeptoren der wachstumsfaktoren aus fibroblasten
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en)	1991-01-11	1993-07-20	Chiron Corporation	Expression and use of human fibroblast growth factor receptor
SG47099A1 (en)	1991-03-15	1998-03-20	Amgen Boulder Inc	Pegylation of polypeptides
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en)	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2145985C (en)	1992-10-28	2003-09-16	Napoleone Ferrara	Vascular endothelial cell growth factor antagonists
US5635388A (en)	1994-04-04	1997-06-03	Genentech, Inc.	Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
EP3260468A1 (en)	1997-04-07	2017-12-27	Genentech, Inc.	Anti-vegf antibodies
EP0973804B1 (en)	1997-04-07	2006-12-27	Genentech, Inc.	Anti-vegf antibodies
AU6366999A (en)	1998-10-30	2000-05-22	Takeda Chemical Industries Ltd.	Betacellulin protein-containing preparations
WO2000046380A2 (en)	1999-02-08	2000-08-10	Chiron Corporation	Fibroblast growth factor receptor-immunoglobulin fusion
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
HUP0302779A3 (en)	2000-06-23	2005-12-28	Schering Ag	Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US6900292B2 (en)	2001-08-17	2005-05-31	Lee-Hwei K. Sun	Fc fusion proteins of human erythropoietin with increased biological activities
WO2004113304A1 (en)	2003-05-22	2004-12-29	Abbott Laboratories	Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
MXPA05012723A (es)	2003-05-30	2006-02-08	Genentech Inc	Tratamiento con anticuerpos anti-vgf.
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
US20060009360A1 (en)	2004-06-25	2006-01-12	Robert Pifer	New adjuvant composition
WO2006076288A2 (en)	2005-01-11	2006-07-20	Five Prime Therapeutics, Inc.	Dna constructs for long-term expression of intravascularly injected naked dna
JP2008528033A (ja)	2005-01-27	2008-07-31	ファイブプライムセラピューティクス，インコーポレイテッド	ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
NZ565511A (en)	2005-07-22	2011-03-31	Five Prime Therapeutics Inc	Compositions and methods of treating disease with FGFR fusion proteins
ES2366160T3 (es) *	2006-11-28	2011-10-17	Aventis Pharma S.A.	Fusiones de fc con receptor para fgf soluble modificadas con actividad biológica mejorada.
CL2007003411A1 (es)	2006-11-28	2008-07-04	Centelion	Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
AR069501A1 (es)	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8614183B2 (en) *	2009-11-13	2013-12-24	Five Prime Therapeutics, Inc.	Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2

2011
- 2011-11-14 KR KR1020187012882A patent/KR101910779B1/ko active IP Right Grant
- 2011-11-14 JP JP2013538985A patent/JP5945277B2/ja not_active Expired - Fee Related
- 2011-11-14 WO PCT/US2011/060666 patent/WO2012068032A1/en active Application Filing
- 2011-11-14 EA EA201390716A patent/EA025828B1/ru not_active IP Right Cessation
- 2011-11-14 NZ NZ610487A patent/NZ610487A/en not_active IP Right Cessation
- 2011-11-14 CA CA2817583A patent/CA2817583A1/en not_active Abandoned
- 2011-11-14 NZ NZ703919A patent/NZ703919A/en not_active IP Right Cessation
- 2011-11-14 CA CA2817537A patent/CA2817537A1/en not_active Abandoned
- 2011-11-14 EP EP11784918.2A patent/EP2640377B1/en active Active
- 2011-11-14 SG SG2013036355A patent/SG190248A1/en unknown
- 2011-11-14 NZ NZ703786A patent/NZ703786A/en not_active IP Right Cessation
- 2011-11-14 NZ NZ610538A patent/NZ610538A/en not_active IP Right Cessation
- 2011-11-14 EA EA201390722A patent/EA201390722A1/ru unknown
- 2011-11-14 CN CN201710017991.8A patent/CN107050426A/zh active Pending
- 2011-11-14 EP EP11790705.5A patent/EP2640406A1/en not_active Withdrawn
- 2011-11-14 MX MX2013005388A patent/MX2013005388A/es unknown
- 2011-11-14 KR KR1020137015424A patent/KR20130114676A/ko not_active Application Discontinuation
- 2011-11-14 KR KR1020137015394A patent/KR20130124513A/ko not_active Application Discontinuation
- 2011-11-14 MX MX2013005387A patent/MX349293B/es active IP Right Grant
- 2011-11-14 AU AU2011329127A patent/AU2011329127B2/en not_active Ceased
- 2011-11-14 CN CN201180064851.7A patent/CN103347514B/zh not_active Expired - Fee Related
- 2011-11-14 SG SG2013036348A patent/SG190788A1/en unknown
- 2011-11-14 AU AU2011329125A patent/AU2011329125B2/en not_active Ceased
- 2011-11-14 BR BR112013012041A patent/BR112013012041A2/pt not_active IP Right Cessation
- 2011-11-14 BR BR112013012040A patent/BR112013012040A2/pt not_active IP Right Cessation
- 2011-11-14 WO PCT/US2011/060661 patent/WO2012068030A1/en active Application Filing
- 2011-11-14 JP JP2013538984A patent/JP6178240B2/ja not_active Expired - Fee Related
2013
- 2013-05-09 IL IL226252A patent/IL226252B/en active IP Right Grant
- 2013-05-09 IL IL226248A patent/IL226248A0/en unknown
- 2013-05-14 ZA ZA2013/03501A patent/ZA201303501B/en unknown
- 2013-05-16 ZA ZA2013/03573A patent/ZA201303573B/en unknown
2016
- 2016-05-27 JP JP2016106022A patent/JP2016196475A/ja active Pending
- 2016-09-08 JP JP2016175357A patent/JP2017019843A/ja active Pending

Also Published As

Publication number	Publication date
CA2817583A1 (en)	2012-05-24
CN107050426A (zh)	2017-08-18
MX349293B (es)	2017-07-21
MX2013005387A (es)	2013-10-17
NZ703919A (en)	2016-04-29
MX2013005388A (es)	2013-11-04
JP2013543870A (ja)	2013-12-09
JP6178240B2 (ja)	2017-08-09
JP2016196475A (ja)	2016-11-24
JP2014500873A (ja)	2014-01-16
WO2012068030A1 (en)	2012-05-24
ZA201303573B (en)	2016-07-27
JP5945277B2 (ja)	2016-07-05
SG190788A1 (en)	2013-07-31
IL226252B (en)	2018-05-31
EA201390722A1 (ru)	2013-11-29
AU2011329125A1 (en)	2013-05-02
AU2011329127A1 (en)	2013-05-02
EA025828B1 (ru)	2017-02-28
EA201390716A1 (ru)	2014-02-28
BR112013012041A2 (pt)	2016-11-08
NZ703786A (en)	2016-08-26
KR20130124513A (ko)	2013-11-14
EP2640377B1 (en)	2018-12-26
AU2011329125B2 (en)	2015-07-30
IL226252A0 (en)	2013-07-31
JP2017019843A (ja)	2017-01-26
CN103347514B (zh)	2017-02-08
CA2817537A1 (en)	2012-05-24
KR20130114676A (ko)	2013-10-18
ZA201303501B (en)	2016-07-27
NZ610538A (en)	2015-02-27
KR20180053420A (ko)	2018-05-21
EP2640406A1 (en)	2013-09-25
EP2640377A1 (en)	2013-09-25
KR101910779B1 (ko)	2018-10-22
CN103347514A (zh)	2013-10-09
SG190248A1 (en)	2013-06-28
WO2012068032A1 (en)	2012-05-24
AU2011329127B2 (en)	2015-09-03
NZ610487A (en)	2015-03-27
IL226248A0 (en)	2013-07-31

Legal Events

Date	Code	Title	Description
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-03	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-08-13	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-09-10	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2019-12-31	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2540 DE 10-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
IL245889A0 (en)	2016-07-31	Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
HK1208186A1 (en)	2016-02-26	Drug protein conjugates
HK1208187A1 (en)	2016-02-26	Drug protein conjugates
HK1177201A1 (zh)	2013-08-16	治療癌症和免疫疾病的作為 -選擇性細胞凋亡誘導劑的磺酰胺衍生物
CO6930321A2 (es)	2014-04-28	Curación de tejidos
LT2582728T (lt)	2017-12-11	Žmogaus antikūno vaisto konjugatai prieš audinių faktorių
BR112014007603A2 (pt)	2017-06-13	métodos de tratamento do câncer
HUE044611T2 (hu)	2019-11-28	Gyógyászati készítmény rák kezelésére
PT2824114T (pt)	2019-08-05	Composição farmacêutica para o tratamento do cancro
ZA201407532B (en)	2016-05-25	Therapeutic uses of fibroblast growthfactor 21 proteins
ZA201300218B (en)	2013-09-25	Treatment of blood cancer
BR112014012880A2 (pt)	2017-06-13	tratamento imunogênico do câncer
BR112015007861A2 (pt)	2018-04-24	prótese de tecido
EP2807180A4 (en)	2016-01-06	PEPTIDE AGENTS USED IN ANTICANCER THERAPY
ITTO20110641A1 (it)	2012-01-16	Composizioni farmaceutiche e metodi di trattamento
BR112013011659A2 (pt)	2016-08-02	métodos de tratamento do câncer
BR112013012040A2 (pt)	2016-08-16	tratamento de câncer com dosagens elevadas de proteínas de fusão fdfr1 solúveis
BR112013013548A2 (pt)	2016-10-11	proteína de fusão anticancerígena
EP2894169A4 (en)	2016-03-02	FUSION PROTEIN WITH AXL AND COMPOSITION FOR CANCER TREATMENT THEREWITH
PT2555790T (pt)	2016-09-09	USO TERAPÊUTICO DA PROTEÍNA DE ß MICROGLOBULINA
IL225624A0 (en)	2013-06-27	Treatment with porphyrin in neurodegenerative diseases
SG11201404312VA (en)	2014-08-28	Method of synthesizing peptides, proteins and bioconjugates
FR2969174B1 (fr)	2014-03-14	Ligand specifique de la proteine lar
FIU20100462U0 (fi)	2010-10-29	Saunasumu
TH112630B (th)	2012-02-28	ยาบำบัดรักษามะเร็งตับ